StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

Research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 2.4 %

Shares of EVOK stock opened at $4.41 on Tuesday. The firm has a market cap of $6.57 million, a price-to-earnings ratio of -0.40 and a beta of 0.16. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $12.84. The company’s 50 day moving average is $4.72 and its 200 day moving average is $5.14.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.